Clinical trials: Premature Retinopathy
Retinopathy of Prematurity, Retinal Detachment
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be…
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Trial name
- ROP (NCT00634972)
- Testing
- ACULAR, REFRESH TEARS
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of South Alabama
Premature Infant Disease, Retinopathy of Prematurity
Pain of Premature Babies and RetCam (DOLICAM)
It is a single-center prospective observational descriptive study. studied population is premature infants, hospitalized in the neonatology department of the University Hospital of Grenoble and for whom the RetCam examination is…
- Trial name
- DOLICAM (NCT04092127)
- Testing
- Video Record
- Where
- France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Grenoble
Retinopathy of Prematurity
Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to…
- Trial name
- NCT02486042
- Testing
- Omegaven, Standard lipids (primarily omega-6 fatty acids)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Diego
Pain, Retinopathy of Prematurity
Reducing Pain and Increasing Comfort During a Retinopathy of Prematurity Examination
The aim of this study is to investigate the effect of baby massage applied to babies with retinopathy of prematurity on the pain and comfort of the newborn.
- Conditions
- Pain, Retinopathy of Prematurity, Premature Baby 26 to 32 Weeks, Premature Baby 33 to 36 Weeks
- Trial name
- NCT06348641
- Testing
- baby massage
- Volunteers
- 60 people
- Sponsor
- Nurgül Tekin
Mechanical Ventilation, Retinal Disease
Cpap at Delivery Room for Preterm Infants
The objective of the study is to determine if CPAP applied within less than 15 min of life in the DR reduces the necessity of mechanical ventilation and surfactant during the first 5 days of life.
- Conditions
- Mechanical Ventilation, Retinal Disease, Death, Respiratory Tract Disease
- Trial name
- CPAP-DR (NCT01024361)
- Testing
- CPAP
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo
Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.
Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP). Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.
- Trial name
- NCT01707745
- Testing
- Intravitreal Bevacizumab
- Where
- United Arab Emirates
- Volunteers
- 50 people
- Sponsor
- Sivakami A Pai
Retinopathy of Prematurity
Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)
The purpose of this study is to provide access to intravitreal injection of Avastin in high-risk infants who do not otherwise qualify for study NCT00702819, an investigational multi-site study examining Avastin use for…
- Trial name
- NCT00870636
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Sponsor
- Children's Hospital Los Angeles
Retinopathy of Prematurity
Infant-parent Skin-to-skin Contact During Screening for Retinopathy
Retinopathy of prematurity (ROP) is a feared complication of premature birth. If discovered in time, the disease can be treated, and impaired vision or blindness can be reduced.
- Trial name
- NCT02780544
- Testing
- skin-to-skin contact, incubator, Sucrose
- Where
- Norway
- Volunteers
- 34 people
- Sponsor
- St. Olavs Hospital
ROP Threshold
39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. Vascular endothelium growth factor (VEGF) is an important component of this disease.
- Trial name
- NCT01993043
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Baylor College of Medicine
Retinopathy of Prematurity
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
In premature infants, propranolol (Prop) treatment might suppress continuing neo-vascularization (NV) and decelerate the progression of retinopathy of prematurity (ROP) towards its severe stages (III-V), thus avoiding the need of…
- Trial name
- NCT01238471
- Testing
- propranolol, sucrose 5%
- Where
- 4 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Retinopathy of Prematurity
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)
The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- NCT02504944
- Testing
- Propranolol 0.2% eye drops
- Where
- 7 sites in Italy
- Volunteers
- 98 people
- Sponsor
- Meyer Children's Hospital IRCCS
Retinopathy of Prematurity
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)
Phase 2, open-label, randomized, multi-center studies in infants and premature infants are necessary to determine treatment and preventative strategies for ROP.
- Trial name
- SPIPROP (NCT02344225)
- Testing
- Caffeine citrate, Ibuprofen, Ketorolac
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- State University of New York - Downstate Medical Center
Retinopathy of Prematurity, Neurodevelopmental Abnormality
Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity
The goal of this research project is to identify the long-term outcome of neurodevelopment in patients with retinopathy of prematurity(ROP) and the treatment of anti-vascular endothelial growth factor (VEGF) such as intravitreal…
- Trial name
- NCT05186155
- Testing
- Severe ROP
- Where
- Taiwan
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital